Cancer risks and mortality in heterozygous ATM mutation carriers

Journal of the National Cancer Institute

Volumn 97, Issue 11, 2005, Pages 813-822

  Thompson, Deborah ^a   Duedal, Silvia ^a   Kirner, Jennifer ^a   McGuffog, Lesley ^a   Last, James ^b   Reiman, Anne ^b   Byrd, Philip ^b   Taylor, Malcolm ^b   Easton, Douglas F ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; PROTEIN SERINE THREONINE KINASE; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; ATAXIA TELANGIECTASIA; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; COLORECTAL CANCER; CONFIDENCE INTERVAL; FEMALE; GENE MUTATION; GENETIC ALGORITHM; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PEDIGREE ANALYSIS; PRIORITY JOURNAL; STOMACH CANCER; ALGORITHM; BREAST TUMOR; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HETEROZYGOTE DETECTION; INCIDENCE; MIDDLE AGED; MORTALITY; MUTATION; NEOPLASM; PEDIGREE; PHENOTYPE; RISK ASSESSMENT; RISK FACTOR; UNITED KINGDOM;

ADULT; AGED; ALGORITHMS; ATAXIA TELANGIECTASIA; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CONFIDENCE INTERVALS; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GREAT BRITAIN; HETEROZYGOTE DETECTION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; PEDIGREE; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES; RISK ASSESSMENT; RISK FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 20544474516     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji141     Document Type: Article

References (45)

1. Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst 1986;77:89-92.
2. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995;268:1749-53.
3. Swift M, Morrell D, Cromartie E, Chamberlin AR, Skolnick MH, Bishop DT. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet 1986;39:573-83.
4. FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, Harkin DP, et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 1997;15:307-10.
5. Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987;316:1289-94.
6. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991;325:1831-6.
7. Inskip HM, Kinlen LJ, Taylor AM, Woods CG, Arlett CF. Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia. Br J Cancer 1999;79:1304-7.
8. Janin N, Andrieu N, Ossian K, Lauge A, Croquette MF, Griscelli C, et al. Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br J Cancer 1999;80:1042-5.
9. Olsen JH, Hahnemann JM, Borresen-Dale AL, Brondum-Nielsen K, Hammarstrom L, Kleinerman R, et al. Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries. J Natl Cancer Inst 2001;93:121-7.
10. Su Y, Swift M. Mortality rates among carriers of ataxia-telangiectasia mutant alleles. Ann Intern Med 2000;133:770-8.
11. Easton DF. Cancer risks in A-T heterozygotes. Int J Radiat Biol 1994;66:S177-82.
12. Geoffroy-Perez B, Janin N, Ossian K, Lauge A, Croquette MF, Griscelli C, et al. Cancer risk in heterozygotes for ataxia-telangiectasia. Int J Cancer 2001;93:288-93.
13. Bebb DG, Yu Z, Chen J, Telatar M, Gelmon K, Phillips N, et al. Absence of mutations in the ATM gene in forty-seven cases of sporadic breast cancer. Br J Cancer 1999;80:1979-81.
14. Buchholz TA, Weil MM, Ashorn CL, Strom EA, Sigurdson A, Bondy M, et al. A Ser49Cys variant in the ataxia telangiectasia, mutated, gene that is more common in patients with breast carcinoma compared with population controls. Cancer 2004;100:1345-51.
15. Izatt L, Greenman J, Hodgson S, Ellis D, Watts S, Scott G, et al. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes Chromosomes Cancer 1999;26: 286-94.
16. Shafman TD, Levitz S, Nixon AJ, Gibans LA, Nichols KE, Bell DW, et al. Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor. Genes Chromosomes Cancer 2000;27:124-9.
17. Thorstenson YR, Roxas A, Kroiss R, Jenkins MA, Yu KM, Bachrich T, et al. Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res 2003;63:3325-33.
18. Chen J, Birkholtz GG, Lindblom P, Rubio C, Lindblom A. The role of ataxia-telangiectasia heterozygotes in familial breast cancer. Cancer Res 1998;58:1376-9.
19. Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X, et al. Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 2002;94:205-15.
20. Dork T, Bendix R, Bremer M, Rades D, Klopper K, Nicke M, et al. Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res 2001;61:7608-15.
21. Gatti RA, Tward A, Concannon P. Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol Genet Metab 1999;68:419-23.
22. Stankovic T, Kidd AM, Sutcliffe A, McGuire GM, Robinson P, Weber P, et al. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet 1998;62:334-45.
23. Bernstein JL, Bernstein L, Thompson WD, Lynch CF, Malone KE, Teitelbaum SL, et al. ATM variants 7271T>G and IVS10-6T>G among women with unilateral and bilateral breast cancer. Br J Cancer 2003; 89:1513-6.
24. Spurdle AB, Hopper JL, Chen X, McCredie MR, Giles GG, Newman B, et al. No evidence for association of ataxia-telangiectasia mutated gene T2119C and C3161G amino acid substitution variants with risk of breast cancer. Breast Cancer Res 2002;4:R15.
25. Stewart GS, Maser RS, Stankovic T, Bressan DA, Kaplan MI, Jaspers NG, et al. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell 1999;99:577-87.
26. Muir C, Waterhouse J, Mack T, Powell J, et al. Cancer incidence in five continents. Vol V. Lyon France: IARC; 1987.
27. Parkin DM, Muir CS, Whelan SL, Gao YT, et al. Cancer incidence in five continents. Vol VI. Lyon France: IARC; 1992.
28. Parkin DM, Whelan SL, Ferlay J, Raymond L, et al. Cancer incidence in five continents. Vol VII. Lyon France: IARC; 1997.
29. Parkin DM, Whelan SL, Ferlay J, Teppo L, et al. Cancer incidence in five continents. Vol VIII. Lyon France: IARC; 2002.
30. Waterhouse JAH, Muir C, Correa P, Powell J. Cancer incidence in five continents. Vol III. Lyon France: IARC; 1976.
31. Waterhouse JAH, Muir C, Shanmugaratnam K, Powell J. Cancer incidence in five continents. Vol IV. Lyon France: IARC; 1982.
32. Coleman MP, Hermon C, Douglas A. Person-years PYRS - a fortran program for cohort study analysis. IARC internal report 89/006. Lyon (France): IARC; 1989.
33. Breslow NE, Day NE. Statistical methods in cancer research. Vol II - the design and analysis of cohort studies. Lyon France: IARC; 1987.
34. Lange K, Weeks D, Boehnke M. Programs for pedigree analysis: MENDEL, FISHER, and dGENE. Genet Epidemiol 1988;5:471-2.
35. Dempster AP, Laird NM, Rubin DB. Maximum likelihood from incomplete data via the EM algorithm (with discussion). J Roy Stat Soc Series B 1977;39:1-38.
36. Louis T. Finding the observed information matrix when using the EM algorithm. J Roy Stat Soc Series B 1982;44:226-33.
37. Stewart GS, Last JI, Stankovic T, Haites N, Kidd AM, Byrd PJ, et al. Residual ataxia telangiectasia mutated protein function in cells from ataxia telangiectasia patients, with 5762ins137 and 7271T->G mutations, showing a less severe phenotype. J Biol Chem 2001;276:30133-41.
38. McConville CM, Stankovic T, Byrd PJ, McGuire GM, Yao QY, Lennox GG, et al. Mutations associated with variant phenotypes in ataxia-telangiectasia. Am J Hum Genet 1996;59:320-30.
39. Sutton IJ, Last JI, Ritchie SJ, Harrington HJ, Byrd PJ, Taylor AM. Adult-onset ataxia telangiectasia due to ATM 5762ins 137 mutation homozygosity. Ann Neurol 2004;55:891-5.
40. World Health Organization. International statistical classification of diseases and related health problems, 1989 revision. Vol 1. Geneva (Switzerland): World Health Organization; 1992.
41. Theunissen JW, Kaplan MI, Hunt PA, Williams BR, Ferguson DO, Alt FW, et al. Checkpoint failure and chromosomal instability without lymphomagenesis in Mre11(ATLD1/ATLD1) mice. Mol Cell 2003;12:1511-23.
42. Cavaciuti E, Lauge A, Janin N, Ossian K, Hall J, Stoppa-Lyonnet D, et al. Cancer risk according to type and location of ATM mutation in ataxia-telangiectasia families. Genes Chromosomes Cancer 2005;42:1-9.
43. Fernet M, Moullan N, Lauge A, Stoppa-Lyonnet D, Hall J. Cellular responses to ionising radiation of AT heterozygotes: differences between missense and truncating mutation carriers. Br J Cancer 2004;90:866-73.
44. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004;351:427-37.
45. National Institute of Clinical Excellence Guidelines, CG0143 Familial Breast Cancer. Available at: http://www.nice.org.uk/CG014NICEguideline. [Last accessed: April 28, 2005.]